The ABSORB bioresorbable vascular scaffold: An evolution or revolution in interventional cardiology?

Hellenic Journal of Cardiology

Volumn 53, Issue 4, 2012, Pages 301-309

  Gogas, Bill D ^a   Farooq, Vasim ^a   Onuma, Yoshinobu ^a   Serruys, Patrick W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Bioresorbable vascular scaffold; Coronary artery disease

Indexed keywords

BIOMATERIAL; EVEROLIMUS; POLYLACTIDE; TISSUE SCAFFOLD;

BARE METAL STENT; CARDIOLOGY; DRUG ELUTING STENT; HUMAN; INTERVENTIONAL CARDIOVASCULAR PROCEDURE; MEDICAL DEVICE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; REVIEW;

ANGIOPLASTY, BALLOON, CORONARY; BIOCOMPATIBLE MATERIALS; CORONARY ARTERY DISEASE; DRUG-ELUTING STENTS; HUMANS; RESEARCH;

EID: 84864650159     PISSN: 11099666     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Grüntzig A. Transluminal dilatation of coronary-artery stenosis. Lancet. 1978; 1: 263.
2. Stefanadis CI. Stents for coronary artery disease: from covered to drug-eluting to bioabsorbable. Hellenic J Cardiol. 2012; 53: 89-90.
3. Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med. 1994; 331: 489-495.
4. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002; 346: 1773-1780.
5. Garg S, Serruys PW. Coronary stents: current status. J Am Coll Cardiol. 2010; 56: S1-42.
6. Garg S, Serruys PW. Coronary stents: looking forward. J Am Coll Cardiol. 2010; 56: S43-78.
7. Byrne RA, Eberle S, Kastrati A, et al. Distribution of angiographic measures of restenosis after drug-eluting stent implantation. Heart. 2009; 95: 1572-1578.
8. Sousa JE, Costa MA, Abizaid A, et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation. 2001; 103: 192-195.
9. Räber L, Wohlwend L, Wigger M, et al. Five-year clinical and angiographic outcomes of a randomized comparison of sirolimus-eluting and paclitaxel-eluting stents: results of the Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization LATE trial. Circulation. 2011; 123: 2819-2828.
10. Ormiston JA, Serruys PW, Regar E, et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet. 2008; 371: 899-907.
11. Serruys PW, Ormiston JA, Onuma Y, et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet. 2009; 373: 897-910.
12. Serruys PW, Onuma Y, Ormiston JA, et al. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes. Circulation. 2010; 122: 2301-2312.
13. Onuma Y, Serruys PW, Perkins LE, et al. Intracoronary optical coherence tomography and histology at 1 month and 2, 3, and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: an attempt to decipher the human optical coherence tomography images in the ABSORB trial. Circulation. 2010; 122: 2288-2300.
14. Gogas BD, Radu M, Onuma Y, et al. Evaluation with in vivo optical coherence tomography and histology of the vascular effects of the everolimus-eluting bioresorbable vascular scaffold at two years following implantation in a healthy porcine coronary artery model: implications of pilot results for future pre-clinical studies. Int J Cardiovasc Imaging. 2012; 28: 499-511.
15. Dudek D, Onuma Y, Ormiston JA, Thuesen L, Miquel-Hebert K, Serruys PW. Four-year clinical follow-up of the ABSORB everolimus-eluting bioresorbable vascular scaffold in patients with denovo coronary artery disease: the ABSORB trial. EuroIntervention. 2012; 7: 1060-1061.
16. Serruys PW, Ong AT, Piek JJ, et al. A randomized comparison of a durable polymer Everolimus-eluting stent with a bare metal coronary stent: The SPIRIT first trial. EuroIntervention. 2005; 1: 58-65.
17. Serruys PW, Onuma Y, Dudek D, et al. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. J Am Coll Cardiol. 2011; 58: 1578-1588.
18. Sarno G, Onuma Y, Garcia Garcia HM, et al. IVUS radiofrequency analysis in the evaluation of the polymeric struts of the bioabsorbable everolimus-eluting device during the bioabsorption process. Catheter Cardiovasc Interv. 2010; 75: 914-918.
19. Okamura T, Serruys PW, Regar E. Cardiovascular flashlight. The fate of bioresorbable struts located at a side branch ostium: serial three-dimensional optical coherence tomography assessment. Eur Heart J. 2010; 31: 2179.
20. Gogas BD, van Geuns RJ, Farooq V, et al. Three-dimensional reconstruction of the post-dilated ABSORB everolimuseluting bioresorbable vascular scaffold in a true bifurcation lesion for flow restoration. JACC Cardiovasc Interv. 2011; 4: 1149-1150.
21. van Geuns RJ, Gogas BD, Farooq V, Regar E, Serruys PW. 3-Dimensional reconstruction of a bifurcation lesion with double wire after implantation of a second generation everolimus-eluting bioresorbable vascular scaffold. Int J Cardiol. 2011; 153: e43-45.
22. Gomez-Lara J, Garcia-Garcia HM, Onuma Y, et al. A comparison of the conformability of everolimus-eluting bioresorbable vascular scaffolds to metal platform coronary stents. JACC Cardiovasc Interv. 2010; 3: 1190-1198.
23. Albiero R, Nishida T, Adamian M, et al. Edge restenosis after implantation of high activity (32) P radioactive beta-emitting stents. Circulation. 2000; 101: 2454-2457.
24. Gogas BD, Serruys PW, Diletti R, et al. Vascular response of the segments adjacent to the proximal and distal edges of the ABSORB everolimus eluting bioresorbable vascular scaffold: months and 1 year follow-up assessment. JACC Cardiovasc Interv. 2012; 5: 656-665.
25. Ozaki Y, Okumura M, Ismail TF, et al. The fate of incomplete stent apposition with drug-eluting stents: an optical coherence tomography-based natural history study. Eur Heart J. 2010; 31: 1470-1476.
26. Onuma Y, Serruys PW, Ormiston JA, et al. Three-year results of clinical follow-up after a bioresorbable everolimuseluting scaffold in patients with de novo coronary artery disease: the ABSORB trial. EuroIntervention. 2010; 6: 447-453.